Director Mark P. Frissora filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of 33,334 shares of Series D Convertible Preferred Stock in BioAdaptives, Inc. (OTC:BDPT) on November 2, 2026, issued as compensation for board services.

Key Highlights

  • Reporting person: Mark P. Frissora, disclosed as a Director of BioAdaptives, Inc.
  • Transaction date: November 2, 2026, with the form filed November 4, 2026.
  • Securities acquired: 33,334 shares of Series D Convertible Preferred Stock, received as board service compensation under a Board of Directors Agreement dated February 3, 2025.
  • Transaction code: J, indicating a transaction not otherwise covered by standard codes.
  • Post-transaction beneficial ownership: 188,599 shares of Series D Convertible Preferred Stock, held directly.
  • Conversion terms: Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation, with conversion not permitted until six months after issuance (May 2, 2027), except upon liquidation.
  • Voting rights: Each share of Series D Convertible Preferred Stock carries 100 votes on matters put to stockholders, without regard to the beneficial ownership limitation.

BioAdaptives Director Frissora Receives Series D Preferred Stock for Board Services

According to the Form 4 filed November 4, 2026, Mark P. Frissora, a Director of BioAdaptives, Inc. (OTC:BDPT), acquired 33,334 shares of Series D Convertible Preferred Stock on November 2, 2026. The filing states that these shares were issued as compensation for board services pursuant to a Board of Directors Agreement dated February 3, 2025, between the issuer and the reporting person. No cash price is listed for the transaction, which was reported under transaction code J.

Following the reported transaction, the filing discloses that Frissora directly beneficially owns 188,599 shares of Series D Convertible Preferred Stock. The filing describes the par value of the Series D shares as $0.0001 per share. Each share is convertible into 100 shares of common stock (par value $0.0001 per share), meaning the 188,599 preferred shares held would underlie 18,859,900 shares of common stock, subject to a 4.9% beneficial ownership limitation on conversion. The filing specifies that no conversion may occur until six months after the date of issuance, except in the event of liquidation, and that the right to convert does not expire.

On voting matters, the filing states that each share of Series D Convertible Preferred Stock outstanding at the time of a stockholder meeting or consent solicitation is entitled to 100 votes, without regard to the beneficial ownership limitation. The filing identifies no deemed execution date separate from the November 2, 2026 transaction date, and no Table I non-derivative securities transactions were reported in this filing.

What Was Disclosed

Director Mark P. Frissora disclosed the receipt of 33,334 Series D Convertible Preferred Stock shares in BioAdaptives, Inc. as board compensation on November 2, 2026, bringing his directly held total in that class to 188,599 shares, with conversion to common stock locked until May 2, 2027.